TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A prospective study of 276 people with HPV-positive oropharyngeal cancer found that reduced elective nodal radiation was followed by 97% five-year locoregional control and 90.8% overall survival. The results support further study of this approach, but do not establish it as a standard of care; researchers say a multicenter phase III trial is needed.
A prospective study found that reduced-intensity radiation for HPV-positive oropharyngeal cancer was followed by 97% five-year locoregional control and 90.8% overall survival, adding long-term evidence for a treatment-de-escalation strategy. The approach lowered radiation to elective lymph-node regions and omitted some low-risk areas, but the results do not establish it as standard care; an expert not involved in the study said confirmation in a multicenter phase III trial is still needed.
The analysis included 276 patients treated with definitive concurrent chemoradiation and followed for a median of five years. Most received intensity-modulated radiotherapy, while 20 received intensity-modulated proton therapy. The study authors, led by Nancy Y. Lee of Memorial Sloan Kettering Cancer Center, reported that 260 patients had no evidence of disease at five years and 250 were alive at last follow-up.
The regimen gave 30 Gy in 15 fractions to elective nodal and subclinical regions, followed by a sequential 40-Gy boost to areas requiring higher treatment. It also omitted selected low-risk nodal basins. The reported five-year outcomes included 97.0% locoregional control, 91.2% distant metastasis-free survival, 90.8% overall survival and 85.9% progression-free survival. These measures describe different outcomes and should not be treated as interchangeable.
The authors reported no treatment failures in nodal basins that were omitted. One elective nodal failure occurred in a contralateral lymph node that had been indeterminate on imaging at baseline and received 30 Gy. Distant-only recurrences occurred in 23 patients. The report also said that, apart from one locoregional failure, such recurrences were in areas with known residual macroscopic disease.
Lower Nodal Radiation, Durable Control
Elective nodal irradiation treats lymph-node regions considered at risk even when cancer is not visible there. Reducing its dose or the volume treated may limit radiation exposure to normal tissues involved in saliva production and swallowing, potentially reducing treatment burden for patients. The study authors said their strategy was designed to lower that exposure while maintaining cancer control.
David Sher of UT Southwestern Medical Center, who was not involved in the research, told MedPage Today that elective nodal radiation can contribute substantially to dose received by normal tissues. He described the outcomes as encouraging, while cautioning that the study did not report quality-of-life data. The results therefore show long-term cancer outcomes for this group, not a direct measurement of whether patients experienced fewer lasting side effects.
The findings matter because they extend earlier follow-up of the same de-escalation strategy, which had reported two-year outcomes. Five-year results offer a longer view of disease control, but a prospective study alone does not establish that this regimen is equivalent or superior to conventional treatment across care settings.
Products Worth Considering
Philips Sonicare ProtectiveClean 5300 Rechargeable Electric Toothbrush, Black, with 3 Brush Heads
Theragun Relief Special Edition Bundle
TheraGun Therabody Relief Massage Gun
As an affiliate, we earn on qualifying purchases.
How the Reduced-Dose Regimen Worked
The study focused on HPV-positive oropharyngeal cancer, a cancer of the throat area that includes the tonsils and base of the tongue. The treatment was not radiation alone: patients received concurrent chemoradiation, predominantly with platinum-based chemotherapy. The study authors emphasized that reducing elective nodal radiation within a curative treatment plan differs from removing chemotherapy.
Participants received intensity-modulated radiation therapy or proton therapy. The lower 30-Gy dose was directed at elective nodal and subclinical regions, while a sequential boost treated areas designated for higher doses. The investigators also left out selected uninvolved nodal levels, including low-risk regions. According to the authors, none of the omitted basins later had a recorded failure.
Sher noted that all patients had PET-CT imaging and most also had MRI. He said advanced imaging may help identify small lymph nodes that could harbor cancer and need a higher dose. He also pointed out that the report did not specify how many equivocal lymph nodes received higher-dose treatment. Those details matter when judging how readily the approach could be applied to other patients.
“The degree of success is remarkable given the extent of dose reduction.”
— David Sher, UT Southwestern Medical Center
Questions Before Wider Adoption
The study reports favorable outcomes for its participants, but it does not answer whether the regimen performs as well as standard treatment in a randomized comparison across multiple institutions. Sher said a phase III randomized trial is needed to confirm non-inferiority. Until such evidence is available, the results should not be read as proof that every patient with HPV-positive oropharyngeal cancer can safely receive less radiation.
The report also did not provide quality-of-life results for this analysis, so the extent of any reduction in swallowing, salivary or other treatment effects remains unquantified here. It is also unclear from the report how many equivocal lymph nodes received a higher radiation dose. Imaging, chemotherapy use and patient selection may all affect how the results apply to other treatment settings.
Although the study included people across T- and N-stage groups and smoking histories, the reported figures do not by themselves identify which individual patients are suitable candidates. Decisions about treatment require clinical assessment; the study is evidence about a defined regimen, not personal medical guidance.
A Multicenter Trial Is Needed
The next evidence milestone is a randomized, multicenter phase III trial comparing the reduced-dose approach with standard treatment and testing whether cancer control is non-inferior. Sher said such a trial would be needed before the strategy could be considered a true standard of care. The source report did not identify a trial launch date or provide details of a planned study.
Further reporting should also clarify how researchers select patients and nodal regions for reduced-dose treatment, how equivocal imaging findings are handled, and whether lower elective doses translate into measurable quality-of-life benefits. For now, the five-year results add support to continued investigation, while the treatment’s role in routine practice remains unsettled.
Key Questions
What did the five-year study find?
Among 276 patients, the study reported 97.0% five-year locoregional control, 91.2% distant metastasis-free survival and 90.8% overall survival after de-escalated elective nodal radiation given with concurrent chemoradiation.
What was reduced in the treatment?
Elective nodal and subclinical regions received 30 Gy in 15 fractions, with a sequential boost to areas requiring higher doses. The regimen also omitted selected low-risk nodal basins.
Does this mean lower-dose radiation is now standard?
No. The findings add long-term evidence from a prospective study, but the source report says a multicenter phase III randomized trial is still needed to confirm non-inferiority before the approach can be established as standard care.
Did the study show fewer long-term side effects?
The report did not provide quality-of-life data for this analysis. Researchers and an outside expert discussed the potential to reduce exposure to normal tissues, but the five-year cancer outcomes do not quantify whether patients experienced fewer side effects.
Were patients treated with radiation alone?
No. Patients received concurrent chemoradiation, predominantly with platinum-based chemotherapy, alongside the reduced elective nodal radiation regimen.
Source: medpagetoday.com
